Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Fusion Pharmaceuticals to Acquire Phase 2 Program for 225Ac-PSMA I&T, a Radiopharmaceutical Targeting Metastatic Castrate Resistant Prostate Cancer
Fusion Pharmaceuticals, a clinical-stage oncology company focused on developing next-generation targeted alpha therapies as precision […]
MCRA Assists TriReme Medical with Obtaining FDA Premarket Approval of Cardiovascular Balloon Catheter
MCRA, a leading medical device-focused regulatory advisory firm and clinical research organization (CRO) integrating US […]
U.S. Government and Novavax Extend Partnership, Securing Up to 1.5 Million Additional Doses of Novavax' COVID-19 Vaccine
Novavax, a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, […]
LegoChem Biosciences Signs License Agreement to Acquire First-in-class Antibody From Elthera
LegoChem Biosciences announced on February 13, 2023 a license agreement with Elthera AG, a biotechnology […]
B dot Medical to Install Ultra-compact Proton Therapy System at Thammasat University in Thailand
B dot Medical and Thammasat University, a leading national university in Thailand, have signed a memorandum […]
Silver Creek Presents ARPEGGIO, a Phase 2 Clinical Trial Evaluating Scp776, a First-in-Class Cell Rescue Drug, for the Treatment of Acute Ischemic Stroke
Silver Creek, a biotechnology company headquartered in San Francisco, presented the ARPEGGIO study at the […]
First Patient in the US Dosed in a Global Multicentre Phase 3 Clinical Study of Bevacizumab for treatment of Ophthalmic Diseases
Essex Bio-Technology today announced that the first patient in the United States (US) was dosed […]
Phio Pharmaceuticals Announces Positive DMC Recommendation and Continued Enrollment of Advanced Melanoma Study Without Modification
Phio Pharmaceuticals, a clinical-stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to […]
Nona Biosciences Enters into HCAb Based Antibody Discovery Collaboration Agreement with Mythic Therapeutics
Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Limited committed to cutting-edge technology innovations, and […]
Vaxxas Initiates Phase I Clinical Study of First Needle-Free, Inactivated Seasonal Influenza Vaccine
Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, today announced the initiation of […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more